Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Protocol of Herceptin Adjuvant With Reduced Exposure, a Randomised Comparison of 6 Months vs 12 Months in All Women Receiving Adjuvant Herceptin [PHARE].

Trial Profile

Protocol of Herceptin Adjuvant With Reduced Exposure, a Randomised Comparison of 6 Months vs 12 Months in All Women Receiving Adjuvant Herceptin [PHARE].

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Adenocarcinoma; Early breast cancer; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Acronyms PHARE
  • Most Recent Events

    • 01 Aug 2017 Results (n=5502) assessing sequential versus concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer using patient data from NCT00381901 and SIGNAL trials published in the European Journal of Cancer
    • 11 Oct 2016 Results evaluating the impact of HER expression levels in the PHARE/SIGNAL cohort (n=5474; HER2+) presented at the 41st European Society for Medical Oncology Congress
    • 11 Oct 2016 Results of sequential vs concomitant incorporation of trastuzumab with chemotherapy in the PHARE/SIGNAL cohort (n=5502; HER2+) presented at the 41st European Society for Medical Oncology Congress
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top